To date, the FDA has approved thirty biosimilar agents from 10 reference products:

Reference drug: Bevacizumab

Biosimilar(s)

- **Bevacizumab-bvzr**(FDA-approved in June 2019)

- **Bevacizumab-awwb**(FDA-approved in September 2017)

Indications for biosimilar:

- Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy (first-line or second-line therapy).

- Metastatic colorectal cancer, with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy (second-line therapy in subjects who have progressed on a first-line bevacizumab product-containing regimen).

- Non-squamous non-small cell lung cancer (non-resectable, locally advanced, recurrent, or metastatic disease) in sequence with carboplatin and paclitaxel  (first-line therapy).

- Glioblastoma, as monotherapy for adult subjects with progressive disease course following prior therapy.

- Metastatic renal cell carcinoma in combination therapy with interferon alfa.

- Cervical cancer (persistent, recurrent, or metastatic), in sequence with paclitaxel and cisplatin or paclitaxel and topotecan.

Reference drug: Etanercept

Biosimilar(s)

- **Etanercept-ykro**(FDA-approved in April 2019)

- **Etanercept-szzs**(FDA-approved in August 2016)

Indications for biosimilar:

- Rheumatoid arthritis

- Polyarticular juvenile idiopathic arthritis (subjects 2 years and older)

- Psoriatic arthritis

- Ankylosing spondylitis

- Plaque psoriasis (subjects 4 years and older)

Reference drug: Epoetin-alfa

Biosimilar(s)

- **epoetin alfa-epbx**(FDA-approved in May 2018)

Indications of Biosimilar:

- Anemia due to chronic kidney disease (CKD) regardless of dialysis status.

- Anemia from zidovudine use in HIV-infected subjects.

- Anemia due to concurrent use of myelosuppressive chemotherapy (once initiated, at least eight weeks of planned chemotherapy).

- Anemia from the decline of allogeneic RBC transfusions in subjects enduring elective, noncardiac, nonvascular surgery.

Reference drug: Trastuzumab

Biosimilar(s)

- **Trastuzumab-anns**(FDA-approved in June 2019)

- **Trastuzumab-qyyp**(FDA-approved in March 2019)

- **Trastuzumab-dttb**(FDA-approved in January 2019)

- **Trastuzumab-pkrb**(FDA-approved in December 2018)

- **Trastuzumab-dkst**(FDA-approved in December 2017)

Indications of Biosimilar:

- HER2 (human epidermal growth factor receptor 2) associated breast cancer

- HER2 associated gastric (metastatic) or gastroesophageal junction adenocarcinoma

Reference drug: Adalimumab

Biosimilar(s)

- **Adalimumab-fkjp**(FDA-approved in July 2020)

- **Adalimumab-afzb**(FDA-approved in November 2019)

- **Adalimumab-bwwd**(FDA-approved in July 2019)

- **Adalimumab-adaz**(FDA-approved in October 2018)

- **Adalimumab-adbm**(FDA-approved in August 2017)

- **Adalimumab-atto**(FDA-approved in September 2016)

Indications for biosimilar:

- Rheumatoid arthritis

- Juvenile idiopathic arthritis

- Psoriatic arthritis

- Ankylosing spondylitis

- Adult Crohn disease

- Ulcerative colitis

- Plaque psoriasis

Reference drug: Pegfilgrastim

Biosimilar(s)

- **Pegfilgrastim-apgf**(FDA-approved in June 2020)

- **Pegfilgrastim-bmez**(FDA-approved in November 2019)

- **Pegfilgrastim-cbqv**(FDA-approved in November 2018)

- **Pegfilgrastim-jmdb**(FDA-approved in June 2018)

Indications for biosimilar:

- To reduce the occurrence of infection caused by febrile neutropenia in subjects with non-myeloid cancer receiving myelosuppressive antineoplastic agents that have correlations with a clinically significant occurrence of febrile neutropenia.

Reference drug: Filgrastim

Biosimilar(s)

- **Filgrastim-aafi**(FDA-approved in July 2018)

- **Filgrastim-sndz**(FDA-approved in March 2015)

Indications of biosimilar:

- Reduce the occurrence of infection caused by febrile neutropenia in subjects with non-myeloid cancer receiving myelosuppressive antineoplastic agents that are correlated with a clinically significant occurrence of febrile neutropenia.

- Decreasing the duration of neutrophil recovery and the span of fever post-chemotherapy in subjects with acute myeloid leukemia (AML) post-chemotherapy.

- Decreasing the time of neutropenia and neutropenia-associated clinical abnormalities in subjects with non-myeloid cancers receiving myeloablative chemotherapy accompanied by bone marrow transplantation (BMT).

- Decrease the number and extent of severe neutropenia associated abnormalities in symptomatic patients with congenital‚ cyclic, and idiopathic neutropenia.

- Mobilize hematopoietic progenitor cells obtained from the same individual toward the peripheral blood for acquisition by leukapheresis.

Reference drug: Infliximab

Biosimilar(s)

- **infliximab-axxq**(FDA-approved in December 2019)

- **infliximab-qbtx**(FDA-approved in December 2017)

- **infliximab-abda**(FDA-approved in May 2017)

- **infliximab-dyyb**(FDA-approved in April 2016)

Indications for biosimilar:

- Crohn disease

- Pediatric Crohn disease

- Ulcerative colitis

- Rheumatoid arthritis in conjunction with methotrexate

- Psoriatic arthritis

- Plaque psoriasis

Reference drug: Rituximab

Biosimilar(s)

- **Rituximab-arrx**(FDA-approved in December 2020)

- **Rituximab-pvvr**(FDA-approved in July 2019)

- **Rituximab-abbs**(FDA-approved in November 2018)

Indications for biosimilar:

- Granulomatosis with polyangiitis (Wegener Granulomatosis) in adult subjects in conjunction with glucocorticoids.

- Microscopic polyangiitis in adult subjects in conjunction with glucocorticoids.

- Chronic lymphocytic leukemia in adult subjects that were untreated or treated for CD20-positive CLL in sequence with fludarabine and cyclophosphamide (FC).

- Used as solo therapy for low-grade or follicular CD20-positive B-cell non-Hodgkin lymphoma in adult subjects that have relapsed or refractory to treatment.

- Conjunction with first-line chemotherapy for adult patients with follicular, CD20-positive, B-cell non-Hodgkin lymphoma that did not receive therapy earlier.

- Single-agent maintenance therapy for adult patients with follicular, CD20-positive, B-cell non-Hodgkin lymphoma who attained a full or partial response to a rituximab agent in sequence with a chemotherapeutic drug.

- Monotherapy following first-line agents: cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy regimens, for low-grade, CD20-positive, B-cell non-Hodgkin lymphoma that is stable and is not progressing.

- In sequence with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or other anthracycline-based chemotherapeutic regimens in subjects who have not been treated prior for diffuse, large B-cell, CD20-positive non-Hodgkin lymphoma.

Reference drug: Insulin glargine

Biosimilar(s)

- **Insulin glargine-yfgn**(FDA-approved in July 2021)

Indications for biosimilar:

- Adult subjects with type 1 diabetes mellitus and type 2 diabetes mellitus

- Pediatric subjects with type 1 diabetes mellitus